A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

16764D8991C00001-TREVI-OC-01OpenA Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01) D8991C00001 (TREVI-OC-01)NCT07218809IndustrialAdultTreatmentIIIGlobalOvaryHoskins, EbonyMedStar Health and GUMC; Medstar Washington Hospital CenterGyn. Onc.Oncology GroupMHRI Washington Cancer Institute2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>